Skip to main content

Evommune, Inc.

For the period ended Jun 30, 2026. Filed Aug 6, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 6, 2026

EVMN$7.84+2.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Balance Sheets (unaudited)

(in thousands, except share and per share amounts)

June 30, · December 31,
2026 · 2025
Assets
Current assets:
Cash and cash equivalents$60,034$44,063
Short-term investments140,759105,137
Prepaid expenses and other current assets3,4534,278
Total current assets204,246153,478
Operating lease right-of-use assets, net7,5681,469
Property and equipment, net1,650994
Long-term investments87,21467,489
Restricted cash1,2031,415
Other non-current assets66101
Total assets$301,947$224,946
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable$5,044$7,756
Accrued liabilities10,6889,547
Operating lease liability, current portion1,237242
Other current liabilities518364
Total current liabilities17,48717,909
Operating lease liability, non-current portion6,4401,290
Financing lease liability434181
Total liabilities24,36119,380
Stockholders’ equity:
Common stock, par value $0.0001 — 500,000,000 shares authorized at June 30, 2026 and December 31, 2025, respectively; 36,281,767 and 31,524,093 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively43
Additional paid-in capital552,591426,652
Accumulated deficit(275,009)(221,089)
Total stockholders’ equity277,586205,566
Total liabilities and stockholders’ equity$301,947$224,946
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.